DE69133083T2 - Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten - Google Patents

Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten

Info

Publication number
DE69133083T2
DE69133083T2 DE69133083T DE69133083T DE69133083T2 DE 69133083 T2 DE69133083 T2 DE 69133083T2 DE 69133083 T DE69133083 T DE 69133083T DE 69133083 T DE69133083 T DE 69133083T DE 69133083 T2 DE69133083 T2 DE 69133083T2
Authority
DE
Germany
Prior art keywords
paf
lyso
treatment
antagonists
ginkgolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133083T
Other languages
English (en)
Other versions
DE69133083C5 (de
DE69133083D1 (de
Inventor
Ruth-Maria Korth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8207297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69133083(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69133083D1 publication Critical patent/DE69133083D1/de
Publication of DE69133083T2 publication Critical patent/DE69133083T2/de
Publication of DE69133083C5 publication Critical patent/DE69133083C5/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69133083T 1991-11-04 1991-11-04 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten Expired - Lifetime DE69133083C5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91118745A EP0540767B9 (de) 1991-11-04 1991-11-04 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten

Publications (3)

Publication Number Publication Date
DE69133083D1 DE69133083D1 (de) 2002-09-12
DE69133083T2 true DE69133083T2 (de) 2003-05-08
DE69133083C5 DE69133083C5 (de) 2007-05-31

Family

ID=8207297

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69133083T Expired - Lifetime DE69133083C5 (de) 1991-11-04 1991-11-04 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten
DE0540767T Pending DE540767T1 (de) 1991-11-04 1991-11-04 Behandlung und Vorbeugung von von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0540767T Pending DE540767T1 (de) 1991-11-04 1991-11-04 Behandlung und Vorbeugung von von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten

Country Status (6)

Country Link
US (3) US5346894A (de)
EP (1) EP0540767B9 (de)
JP (1) JPH06305981A (de)
AT (1) ATE221779T1 (de)
DE (2) DE69133083C5 (de)
ES (1) ES2181665T3 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895785A (en) * 1987-10-20 1999-04-20 Ruth Korth Treatment and prevention of disorders mediated by LA-paf or endothelial cells
US5530023A (en) * 1987-10-20 1996-06-25 Korth; Ruth Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells
US6274621B1 (en) * 1995-11-09 2001-08-14 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ginkgolides for inhibition of membrane expression of benzodiazepine receptors
US5854279A (en) * 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
US7078434B1 (en) * 1999-08-12 2006-07-18 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Use of Ginkgo extract
JP4733801B2 (ja) * 1999-08-23 2011-07-27 丸善製薬株式会社 エストロゲン様作用剤および皮膚化粧料
US6583152B2 (en) * 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US11039997B2 (en) 2005-12-27 2021-06-22 Ruth-Maria Korth Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
JP5982676B2 (ja) * 2011-02-28 2016-08-31 学校法人 いわき明星大学 抗ｐａｆ活性を有するビオチニル化ペプチド化合物
DE202011108417U1 (de) * 2011-11-29 2012-03-01 Ruth-Maria Korth Örtliche und dietätische Kompositionen ohne Etherlipide, Etherphospholipide, Alkylradikale, die geeignet sind für sensible Personen
CN108096241B (zh) * 2017-11-24 2020-06-16 江苏康缘药业股份有限公司 银杏内酯组合物的医药用途
DE202019003092U1 (de) 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8705890A3 (es) * 1971-06-18 1986-11-16 Yoshitomi Pharmaceutical Un metodo de preparacion de compuesto de triazolotienodiaze-pina
DE3338995A1 (de) * 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Bilobalid enthaltende arzneimittel
DE2732921A1 (de) * 1977-07-21 1979-02-08 Boehringer Sohn Ingelheim Neue substituierte 1-acyl-piperidino- bzw. -piperazino-4h-s-triazolo eckige klammer auf 3,4c eckige klammer zu thieno eckige klammer auf 2,3e eckige klammer zu 1,4- diazepine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
US4183912A (en) * 1978-01-16 1980-01-15 American Home Products Corporation Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine
DE2830782A1 (de) * 1978-07-13 1980-01-24 Boehringer Sohn Ingelheim Neue substituierte 4h-s-triazolo eckige klammer auf 3,4c eckige klammer zu thieno eckige klammer auf 2,3e eckige klammer zu 1,4-diazepine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
JPS6045518A (ja) * 1983-08-22 1985-03-12 Takeda Chem Ind Ltd 抗シヨツク剤
US4540709A (en) * 1983-10-13 1985-09-10 Merck & Co., Inc. Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran
US4595693A (en) * 1984-06-04 1986-06-17 Merck & Co., Inc. Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3502392A1 (de) * 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
ES2037013T3 (es) * 1986-01-21 1993-06-16 Boehringer Ingelheim Kg Procedimiento para preparar tieno-1,4-diazepinas.
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
JPS63225373A (ja) * 1986-07-24 1988-09-20 Sumitomo Pharmaceut Co Ltd 新規チアゾリジン−４−オン誘導体およびその酸付加塩
YU136287A (en) * 1986-07-25 1990-06-30 Boehringer Kg Process for preparing new 1,4 benzodiazepines
DE3710921C2 (de) * 1986-10-21 1996-09-26 Korth Ruth Verwendung der Gingkolide BN 52020, BN 52021 und BN 52063 zur Behandlung von Arteriosklerose
DE3735524C2 (de) * 1986-10-21 1996-07-11 Korth Ruth Maria Verfahren zur Bestimmung des paf-Acether- oder Peak X-Gehaltes von Blut
DE3716004A1 (de) * 1987-05-13 1988-11-24 Bischof Hubert Sicherheitsfolie, deren verwendung und mit dieser hergestelltes sicherheitsglas
DE3735525C2 (de) * 1987-10-20 1997-02-20 Korth Ruth Maria Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten
DE4244265C2 (de) * 1992-12-28 1999-08-12 Korth Ruth Maria Verwendung von Paf-Antagonisten gegen die neue Ausbildung von Paf-Bindungsstellen auf endothelialen Zellen zur Behandlung oder Vorbeugung des Hyperinsulinismus
GB8725871D0 (en) * 1987-11-04 1987-12-09 Scras Ginkgolide derivatives
DE8716044U1 (de) * 1987-12-04 1988-03-24 Lewitz, Reinwald, 3100 Celle, De
US5334592A (en) * 1988-04-27 1994-08-02 Schering Corporation Certain PAF antagonist antihistamine combinations and methods
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
WO1990013299A1 (en) * 1989-05-05 1990-11-15 Northern Sydney Area Health Service Fertility enhancement
IT1238684B (it) * 1990-02-09 1993-09-01 Indena Spa Derivati del bilobalide,loro usi e formulazioni che li contegono
ATE195653T1 (de) * 1990-06-06 2000-09-15 Ruth Korth Behandlung von erkrankungen mit paf-antagonisten und verfahren zur bestimmung deren wirksamkeit

Also Published As

Publication number Publication date
US5605927A (en) 1997-02-25
JPH06305981A (ja) 1994-11-01
EP0540767A1 (de) 1993-05-12
DE69133083C5 (de) 2007-05-31
EP0540767B9 (de) 2004-12-22
EP0540767B1 (de) 2002-08-07
DE540767T1 (de) 2001-10-25
US5346894A (en) 1994-09-13
ES2181665T3 (es) 2003-03-01
DE69133083D1 (de) 2002-09-12
ATE221779T1 (de) 2002-08-15
US5852052A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
DE69133083T2 (de) Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten
DE69328186T2 (de) Zusammensetzung zur behandlung der parkinson-krankheit
ATE142107T1 (de) Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
ATE236654T1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
RU93058351A (ru) Замещенные 3-аминохинуклидины, фармацевтические композиции на его основе, способы лечения, способ получения, промежуточные соединения
KR100935615B1 (ko) 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
BR0116001A (pt) Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
ATE142489T1 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
DE3852773D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ATE106737T1 (de) Pharmazeutische zusammensetzungen zur behandlung gastrointestinaler störungen.
DE69129331T2 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
IT8322855A0 (it) Composizione farmaceutica per la cura delle arteriopatie periferiche.
ATE195653T1 (de) Behandlung von erkrankungen mit paf-antagonisten und verfahren zur bestimmung deren wirksamkeit
HUT61467A (en) Process for producing pharmaceutical compositions comprising quisqualate receptor antagonist quinoxalinedione and suitable for treating parkinson's disease
DE69131553D1 (de) Arzneimittel enthaltend Mischungen von höheren primären aliphatischen Alkoholen zur Behandlung von Hypercholesterolämie und Hyperlipoproteinämie Typ II und zur Stimulation des sexuellen Verhaltens bei Tieren und Menschen
RU2005133478A (ru) Применение производных карбамазепина для лечения возбуждения у пациентов, страдающих деменцией
Lühdorf et al. Motor and sensory conduction velocities and electromyographic findings in man before and after carbamazepine treatment
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
OA09451A (fr) "Nouveaux dérivés de la pyrrolidone, leur procédé de préparation et les compositions pharmaceutiques les renfermant".
EP0398171A3 (de) Verwendung von Imidazodiazepinen bei der Behandlung von neurologischen Symptomen, welche mit zirkulatorischen Störungen des Gehirns assoziiert sind
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8310 Action for declaration of annulment
8312 Partial invalidation
8394 Patent changed during the nullification procedure (changed patent specification reprinted)